Senior Member
|
|
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
|
|
Senior Member
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
|
Am I missing something? If I understand the report on the paper correctly, it contains a curious mixture of data.
E.g. "a significant reduction in total levodopa equivalent daily doses (mg/day) of 50.45% was observed in patients treated with STN-DBS". Although, everything else being equal, this is desirable, it is not the same thing as a 50.45% reduction in symptoms.
E.g. "Most patients reported that expectations of improvement after DBS were met, namely 64% for motor symptoms, 71% for quality of life, and 83% for reductions in daily medication dose." I take this to mean that if I went into the procedure with the expectation that, for some measure, I would get an improvement of 10%, say, and I got this, then I could write that 100% of my expectations in that measure had been met.
John
__________________
Born 1955. Diagnosed PD 2005.
Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg
Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg
|